{
    "organizations": [],
    "uuid": "f0d172ae69f457187de8bf9622a7a19ab479a1e1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-eli-lilly-says-phase-3-study-for-p/brief-eli-lilly-says-phase-3-study-for-patients-with-chronic-cluster-headache-did-not-meet-its-primary-endpoint-idUSB8N1GZ00O",
    "ord_in_thread": 0,
    "title": "BRIEF-Eli Lilly Says Phase 3 Study For Patients With Chronic Cluster Headache Did Not Meet Its Primary Endpoint",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - Eli Lilly and Co:\n* ELI LILLY AND CO - PHASE 3 STUDY FOR PATIENTS WITH CHRONIC CLUSTER HEADACHE DID NOT MEET ITS PRIMARY ENDPOINT\n* ELI LILLY AND CO - CONDUCTED SEPARATE PHASE 3 STUDY FOR PATIENTS WITH CHRONIC CLUSTER HEADACHE, WHICH REPRESENTS 10-15 PERCENT OF CLUSTER HEADACHE CASES\n* ELI LILLY AND CO - OBSERVED SAFETY AND TOLERABILITY PROFILE CONSISTENT WITH PREVIOUS STUDIES THAT EVALUATED GALCANEZUMAB FOR THE PREVENTION OF MIGRAINE\n* LILLYâ€™S GALCANEZUMAB MEETS PRIMARY ENDPOINT IN PHASE 3 STUDY EVALUATING GALCANEZUMAB FOR THE PREVENTION OF EPISODIC CLUSTER HEADACHE Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-15T19:09:00.000+03:00",
    "crawled": "2018-05-16T18:54:29.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "eli",
        "lilly",
        "co",
        "eli",
        "lilly",
        "co",
        "phase",
        "study",
        "patient",
        "chronic",
        "cluster",
        "headache",
        "meet",
        "primary",
        "endpoint",
        "eli",
        "lilly",
        "co",
        "conducted",
        "separate",
        "phase",
        "study",
        "patient",
        "chronic",
        "cluster",
        "headache",
        "represents",
        "percent",
        "cluster",
        "headache",
        "case",
        "eli",
        "lilly",
        "co",
        "observed",
        "safety",
        "tolerability",
        "profile",
        "consistent",
        "previous",
        "study",
        "evaluated",
        "galcanezumab",
        "prevention",
        "migraine",
        "lilly",
        "galcanezumab",
        "meet",
        "primary",
        "endpoint",
        "phase",
        "study",
        "evaluating",
        "galcanezumab",
        "prevention",
        "episodic",
        "cluster",
        "headache",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}